SCHEMBL243971

SCHEMBL243971

CCCS(=O)(=O)[N]S(=O)(=O)CCC

nearest known ligand 0.32

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 2/20 0.32
NPC1 O15118 1/20 0.31
S1PR2 O95136 1/20 0.31
S1PR4 O95977 1/20 0.31
ALDH1A1 P00352 1/20 0.31
LMNA P02545 1/20 0.31
TP53 P04637 1/20 0.31
POLB P06746 1/20 0.31
MAPT P10636 1/20 0.31
HPGD P15428 1/20 0.31
XBP1 P17861 1/20 0.31
S1PR1 P21453 1/20 0.31
MAPK1 P28482 1/20 0.31
AGTR1 P30556 1/20 0.31
HTT P42858 1/20 0.31
RAB9A P51151 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
HSD17B10 Q99714 1/20 0.31
CA1 P00915 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3021420 0.94 CA1 (0.33) CA1
SCHEMBL6698140 0.85
SCHEMBL239450 0.81 ALDH1A1 (0.44) FAAHNPC1S1PR2S1PR4ALDH1A1
SCHEMBL301012 0.79 FAAH (0.50) FAAHNPC1S1PR2S1PR4ALDH1A1
SCHEMBL42330 0.78
SCHEMBL3022830 0.77 FAAH (0.54) FAAHTSHRCA2
SCHEMBL28180615 0.75
SCHEMBL2008849 0.75
SCHEMBL241831 0.74 CA1 (0.35) NPSR1CA1
SCHEMBL7869370 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8084613-B2 Tetrazoyloxime derivative and plant disease control agent NIPPON SODA CO., LTD. (JP) 2011-12-27 US claimed
EP-2687088-B1 AQUEOUS HORTICULTURAL MICROBICIDAL COMPOSITION SUSPENSION NIPPON SODA CO (JP) 2018-08-01 EP disclosed
US-9926274-B2 Process for producing substituted methylamine compound and triazine derivative NIPPON SODA CO., LTD. (JP) 2018-03-27 US disclosed
US-9701642-B2 Method for producing optically active 5-hydroxy-3-ketoester NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2017-07-11 US disclosed
EP-2650283-B1 Process for producing substituted methylamine compound and triazine derivative NIPPON SODA CO (JP) 2017-06-07 EP disclosed
US-9630933-B2 Method for producing 1-H-tetrazole derivative NIPPON SODA CO., LTD. (JP) 2017-04-25 US disclosed
EP-2845853-B1 METHOD FOR PRODUCING 1H-TETRAZOLE DERIVATIVE NIPPON SODA CO (JP) 2017-01-25 EP disclosed
EP-2826773-B1 COMPOUND, METHOD FOR PRODUCING COMPOUND, AND METHOD FOR PURIFYING COMPOUND NIPPON SODA CO (JP) 2016-11-02 EP disclosed
US-20160185734-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE 5-HYDROXY-3-KETOESTER NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2016-06-30 US disclosed
EP-2407461-B1 PROCESS FOR PREPARATION OF 1-ALKYL-5-BENZOYL-1H-TETRAZOLE DERIVATIVES NIPPON SODA CO (JP) 2016-05-18 EP disclosed
WO-2005021562-A2 PHOSPINITE-IMIDAZOLINES AND METAL COMPLEXES THEREOF SOLVIAS AG (CH) 2005-03-10 WO disclosed
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed
EP-1472226-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-11-03 EP disclosed
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-03-25 US disclosed
EP-1326835-A1 BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-07-16 EP disclosed
WO-2003045921-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-06-05 WO disclosed
WO-2002028835-A1 BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-04-11 WO disclosed
US-6331628-B1 REACTING A SUBSTITUTED HALOBENZENE WITH POTASSIUM, SODIUM AND/OR ZINC CYANIDE IN THE PRESENCE OF A METALLIC CATALYST NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2001-12-18 US disclosed
US-4649142-A 3,4-dihydro-1,3-disubstituted-6-(substituted phenylimino)-2(1H)-pyrimidinone useful as cardiotonic agent and anti-allergic agent FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1987-03-10 US disclosed
EP-0166564-A2 Pyrimidone derivatives, preparation thereof and use thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1986-01-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160185734-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE 5-HYDROXY-3-KETOESTER CYP51A1, HSD3B1, CYP3A5 FAAH 678/4885NPC1 2143/4885S1PR2 3268/4885
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors APOB, APOL1, SCARB1 FAAH 543/4885NPC1 64/4885S1PR2 721/4885
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 FAAH 405/4885NPC1 100/4885S1PR2 631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.